| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Orahealth USA is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
East Central Health is a Tofield, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Friends Research Institute Incorporated is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nautilus, Inc. is an iconic industry leader with a rich history and reputation as an innovative company building the best cardio and strength equipment for home use. Known for its family of brands that includes Bowflex®, Nautilus®, and Schwinn® Fitness, Nautilus, Inc. develops, manufacturers and markets branded products that include strength, cardio and fitness accessories through direct and retail channels. With its headquarters and innovation center located in Vancouver, Washington, Nautilus, Inc. employs nearly 500 employees and has offices in Brooklyn Park, Minnesota and Shanghai, China, as well as distribution centers in Portland, Oregon, Columbus, Ohio, and Rotterdam, The Netherlands.